Shield To File ST10 Oral Iron-Deficiency Drug After Strong Phase III Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Shield Therapeutics will use robust Phase III data for its oral iron-deficiency therapy ST10 to seek marketing approval in Europe in the second half of 2014 for iron-deficiency anemia in inflammatory bowel disease, and then a subsequent NDA submission in the U.S. for treating iron-deficiency anemia in pre-dialysis patients with chronic kidney disease.